📊 ARCT Key Takeaways
Is Arcturus Therapeutics Holdings Inc. (ARCT) a Good Investment?
Arcturus Therapeutics is a development-stage biotech facing severe operational challenges with revenue collapsing 46% YoY to just $2.1M, while burning $28.9M in operating losses. The company maintains adequate liquidity with $211.4M cash reserves, but lacks a demonstrated path to profitability or revenue recovery, making it fundamentally distressed despite balance sheet strength.
Arcturus Therapeutics has weak current fundamentals, with revenue down 46.1% year over year, deeply negative operating margin, and substantial cash burn. However, the balance sheet is unusually strong for a loss-making biotech, with $230.91M in cash, low leverage, and solid liquidity that provide meaningful operating runway while management works toward more durable revenue generation and improved operating efficiency.
Arcturus Therapeutics Holdings Inc. Key Strengths (ARCT)
- Strong cash position of $211.4M provides 10+ year operating runway at current burn rate
- Minimal leverage with debt-to-equity of 0.08x and only $15.0M long-term debt
- Excellent liquidity with current ratio of 6.31x, reducing near-term bankruptcy risk
- Very strong liquidity, with a 6.64x current and quick ratio supported by $230.91M in cash
- Low balance-sheet leverage, with debt-to-equity of just 0.07x and only $15.00M in long-term debt
- Net loss and diluted EPS improved year over year despite continued operating pressure
ARCT Stock Risks: Arcturus Therapeutics Holdings Inc. Investment Risks
- Revenue collapse of 46% YoY to critically low $2.1M indicates severe business deterioration
- Massive operating losses of $28.9M with negative operating margin of -1403.7% showing unsustainable unit economics
- Negative operating and free cash flow of -$19.4M annually means cash reserves are only buffer, not sustainable model
- No visible path to profitability or revenue growth despite existing product/asset portfolio
- Revenue fell 46.1% year over year, indicating weak growth quality and likely dependence on lumpy or non-recurring revenue sources
- Core profitability remains poor, with a -93.0% operating margin and -80.2% net margin
- Free cash flow was -$74.50M, so sustained cash burn could materially reduce financial flexibility if revenue does not recover
Key Metrics to Watch
- Revenue growth rate and ability to stabilize/reverse 46% decline
- Operating cash flow trajectory and timeline to positive cash generation
- Cash burn rate relative to remaining reserves and runway
- FDA approvals or clinical trial results that could restore revenue streams
- Quarterly revenue consistency and whether top-line growth becomes recurring rather than episodic
- Operating cash burn and free cash flow relative to the current cash balance
Arcturus Therapeutics Holdings Inc. (ARCT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.31x current ratio provides a solid financial cushion.
ARCT Profit Margin, ROE & Profitability Analysis
ARCT vs Healthcare Sector: How Arcturus Therapeutics Holdings Inc. Compares
How Arcturus Therapeutics Holdings Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Arcturus Therapeutics Holdings Inc. Stock Overvalued? ARCT Valuation Analysis 2026
Based on fundamental analysis, Arcturus Therapeutics Holdings Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Arcturus Therapeutics Holdings Inc. Balance Sheet: ARCT Debt, Cash & Liquidity
ARCT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Arcturus Therapeutics Holdings Inc.'s revenue has grown significantly by 702% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.12 indicates the company is currently unprofitable.
ARCT Revenue Growth, EPS Growth & YoY Performance
ARCT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.1M | -$14.1M | $-0.52 |
| Q3 2025 | $17.2M | -$6.9M | $-0.26 |
| Q2 2025 | $28.3M | -$9.2M | $-0.34 |
| Q1 2025 | $29.4M | -$14.1M | $-0.52 |
| Q3 2024 | $41.7M | -$6.9M | $-0.26 |
| Q2 2024 | $10.5M | -$1.8M | $-0.07 |
| Q1 2024 | $38.0M | -$26.8M | $-1.00 |
| Q3 2023 | $13.4M | -$16.2M | $-0.61 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Arcturus Therapeutics Holdings Inc. Dividends, Buybacks & Capital Allocation
ARCT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Arcturus Therapeutics Holdings Inc. (CIK: 0001768224)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARCT
What is the AI rating for ARCT?
Arcturus Therapeutics Holdings Inc. (ARCT) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 76% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARCT's key strengths?
Claude: Strong cash position of $211.4M provides 10+ year operating runway at current burn rate. Minimal leverage with debt-to-equity of 0.08x and only $15.0M long-term debt. ChatGPT: Very strong liquidity, with a 6.64x current and quick ratio supported by $230.91M in cash. Low balance-sheet leverage, with debt-to-equity of just 0.07x and only $15.00M in long-term debt.
What are the risks of investing in ARCT?
Claude: Revenue collapse of 46% YoY to critically low $2.1M indicates severe business deterioration. Massive operating losses of $28.9M with negative operating margin of -1403.7% showing unsustainable unit economics. ChatGPT: Revenue fell 46.1% year over year, indicating weak growth quality and likely dependence on lumpy or non-recurring revenue sources. Core profitability remains poor, with a -93.0% operating margin and -80.2% net margin.
What is ARCT's revenue and growth?
Arcturus Therapeutics Holdings Inc. reported revenue of $2.1M.
Does ARCT pay dividends?
Arcturus Therapeutics Holdings Inc. does not currently pay dividends.
Where can I find ARCT SEC filings?
Official SEC filings for Arcturus Therapeutics Holdings Inc. (CIK: 0001768224) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARCT's EPS?
Arcturus Therapeutics Holdings Inc. has a diluted EPS of $-0.95.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ARCT's fundamental grade?
Based on our AI fundamental analysis in June 2026, Arcturus Therapeutics Holdings Inc. has a C grade with 76% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ARCT stock overvalued or undervalued?
Valuation metrics for ARCT: ROE of -14.1% (sector avg: 15%), net margin of -1,308.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ARCT's AI grade for 2026?
Our dual AI analysis gives Arcturus Therapeutics Holdings Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARCT's free cash flow?
Arcturus Therapeutics Holdings Inc.'s operating cash flow is $-19.4M, with capital expenditures of $0.0. FCF margin is -943.3%.
How does ARCT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,308.3% (avg: 12%), ROE -14.1% (avg: 15%), current ratio 6.31 (avg: 2).